Abstract 1916P
Background
Dual ICI therapy is the standard of care for first-line PM patients (pts); single agent ICI improved survival vs placebo in pretreated pts. However, ICI efficacy is comprehensively unsatisfactory in PM, and no biomarkers predict response to therapy. We aimed to identify tumor features correlated with ICI efficacy in PM pts.
Methods
The NIBIT-EPI-MESO is a multicenter study led by the NIBIT Foundation in ICI-treated PM pts. Pts with irPR or irSD were classified as responders (R), those with irPD as non-responders (NR). Tumor biopsies underwent multi-omics analyses: RNA-seq, WES, RRBS, and multiplex immunofluorescence (mIF). Results were correlated with clinical outcome.
Results
Among 73 pts studied 54 had epithelioid, 16 biphasic, and 3 sarcomatoid PM; 64 received ICI as second/third line: 27 tremelimumab plus durvalumab (Calabrò, TLRM 2018), 36 nivolumab plus ipilimumab (Italian expanded access), 10 tremelimumab monotherapy (Calabrò, TLRM 2015). IrPR, irSD, and irPD were achieved by 27%, 36% and 37% of pts. Methylation profiling clustered pts into four subtypes: Demethylated, Low, Intermediate, and CIMP (hypermethylated). The Low cluster was enriched in R pts (22/41; p=0.01) who had the highest mOS (970 days), whereas the CIMP cluster was enriched in NR pts who had the worst mOS (288 days). Also, the Low cluster was the most predictive of ICI outcome in a multivariate model including sex, age, TMB, INFg gene expression (HR=0.1, CI: 0.02-0.47; p=0.003). An enriched proliferation and mitochondrial metabolism characterized the CIMP cluster, while the Low cluster was enriched in pathways associated with innate/adaptive immune response. The Low cluster had higher densities of tumor-associated CD8+ T (p=0.032) and CD20+ B cells (p=0.01) by mIF, compared to CIMP tumors. Tumor and stroma CD20+ B cells associated with response (p=0.016 and p=0.043), tumor CD4+ (p=0.009), CD8+ (p=0.01), CD68+(p=0.017) associated with OS. The low mutational rate identified did not associate with ICI response or OS.
Conclusions
Tumor methylation drives efficacy of ICI therapy in PM pts by shaping tumor immune contextures, regardless of PM histology and TMB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC Foundation (ID.21073); Ministry of Health, Lombardy and Tuscany regions (NET-2016-02361632).
Disclosure
L. Calabro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Merck Sharp Dohme; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, AstraZeneca, Sanofi. F.P. Caruso, T. Noviello: Other, Personal, Stocks/Shares: Immunomics. A. Covre, S. Coral: Other, Personal, Stocks/Shares: Epigen Therapeutics. F. Grosso: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Novocure, Novartis, Pierre Fabre, Merck Sharp Dohme, PharmaMar. A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Pierre Fabre, GSK, Bristol Myers Squibb, Merck Sharp Dohme, Sunpharma, Immunocore, Sanofi; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre, Sanofi. M. Ceccarelli: Other, Personal, Stocks/Shares: Immunomics; Financial Interests, Personal, Speaker, Consultant, Advisor: Moderna Therapeutics. M. Maio: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Pierre Fabre, Merck Serono, Amgen, Eli Lilly, Roche, Merck Sharp Dohme, Incyte, AstraZeneca, GSK, Sciclone, Sanofi, Alfasigma; Other, Personal, Stocks/Shares: Epigen Therapeutics, Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18